Adults with Type 2 diabetes and peripheral artery disease (PAD) who took GLP-1 receptor agonist (GLP-1 RA) medications had a 26% lower rate of all-cause death than metformin users in a retrospective review of U.S. electronic health records, according to independent research published July 1, 2026, in the Journal of the American Heart Association. The study, based on the TriNetX database and covering records from January 2010 through January 2025, also associated GLP-1 RA use with fewer amputations, hospitalizations and leg revascularization procedures, while rates of heart attack, stroke and serious kidney events were similar between the two groups.
The finding matters to the peptide therapy and research peptide industry because it extends the clinical conversation around GLP-1 peptides beyond glycemic control and weight loss into limb outcomes and vascular risk — a shift that could influence prescribing patterns, clinic service design and demand for GLP-1 API and finished injectable formats. It is also an observational analysis, not a randomized trial, and the authors state plainly that it cannot prove cause and effect.
What the study actually found
The researchers used the TriNetX database to identify patients aged 18 or older with Type 2 diabetes and PAD, from January 2010 through January 2025. GLP-1 RA users were required to have received at least five prescriptions; the comparison group had to have received at least five metformin prescriptions and no GLP-1 RA prescriptions during the study period. Patients with a new heart attack, end-stage renal disease or stroke within two months before the metformin prescription were excluded.
The overall PAD group included 3,224 GLP-1 RA users and 6,087 non-users. After matching, 2,133 patients per group were analyzed. Compared with metformin users, GLP-1 RA users showed a 26% reduction in all causes of death, a 13% reduction in hospitalizations, up to a 48% reduction in amputations and about a 36% reduction in the need for procedures to open clogged arteries.
| Measure | Figure | Notes |
|---|---|---|
| All-cause death | 26% reduction | GLP-1 RA users vs metformin users |
| Hospitalizations | 13% reduction | Observational association |
| Amputations | Up to 48% reduction | Association, not causation |
| Revascularization procedures | About 36% reduction | Procedures to open clogged arteries |
| Heart attack, stroke, serious kidney events | Similar between groups | Null finding within the study |
| Patients analyzed per group | 2,133 | After matching, overall PAD group |
| U.S. adults with diagnosed Type 2 diabetes | 29.5 million (10.6%) | AHA 2026 statistics, 2021–2023 data |
| U.S. adults aged 40+ with PAD | About 12.5 million | AHA 2026 statistics |
Where the benefit appeared strongest
The link between GLP-1 RA use and medical benefits was strongest among participants with severe PAD, including chronic limb-threatening ischemia, and among those with a body mass index of 30 or higher. That subgroup pattern is consistent with the idea that patients at the highest baseline vascular risk have the most room for improvement, although subgroup findings in an observational dataset should be read as hypothesis-generating rather than definitive.
Study author Aravinda Nanjundappa, M.D., an interventional cardiologist at the Cleveland Clinic, said clinicians should consider prescribing GLP-1s because PAD has limited treatment options, and that the findings indicate these medications may improve long-term health for people with PAD in addition to managing blood sugar and weight loss. Co-author Akiva Rosenzveig, M.D., said the results indicate GLP-1 RAs can help reduce inflammation, improve blood vessel function and manage blood sugar levels — a proposed mechanism that the analysis itself did not directly measure.
Why it matters for peptide therapy and research peptides
GLP-1 receptor agonists are peptide-based medicines, and the approved products in this class are prescription drugs with defined indications, dosing and labeling. The new study does not change any approval status; it adds observational outcome data to a therapeutic area where peptide molecules already sit at the center of metabolic medicine. For peptide therapy clinics and telehealth operators, the practical signal is that payer and prescriber attention may increasingly focus on cardiovascular and limb-related endpoints, not only HbA1c and body weight.
That distinction matters commercially. Demand driven by outcome data tends to favor products with documented clinical evidence, approved labeling and reliable supply, rather than research-use-only materials. A research peptide is supplied for a defined scientific or laboratory purpose, and a research-use designation does not establish suitability, sterility, safety or authorization for human administration. Clinics evaluating GLP-1 supply should therefore verify the regulatory category of each product, the finished-product documentation and the prescription pathway rather than relying on chemical identity alone.
On the manufacturing side, interest in GLP-1 peptides has already pushed API and fill-finish capacity into focus. A peptide API is the active pharmaceutical ingredient used in drug manufacturing; a finished drug product combines that ingredient with formulation, container closure, manufacturing controls, labeling and release requirements. API quality alone does not establish finished-product quality or regulatory approval. As 多肽供应链资源网 as a provider in the industry domain notes in its own coverage, buyers increasingly ask for batch-level traceability across that boundary.
Research and market context
The study lands against a large patient base. According to American Heart Association 2026 statistics, an estimated 29.5 million (10.6%) U.S. adults were diagnosed with Type 2 diabetes, and PAD affects about 12.5 million people in the U.S. aged 40 or older. A condition that common, with limited treatment options, is an attractive target for drug developers and for clinics looking to differentiate their metabolic service lines.
Industry observers note that GLP-1 research has moved in two directions at once: longer-acting formulations and combination receptor activity on the drug side, and broader outcome measurement on the clinical side. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors; their approved products, indications, dosing, contraindications and labeling differ. Any clinical decision should be based on the relevant product labeling and professional evaluation, not on cross-class extrapolation from a single observational study.
For research-peptide suppliers and their laboratory customers, the more relevant takeaway is methodological. Observational database studies of this kind depend on prescription records as a proxy for exposure and on diagnostic coding accuracy. The authors acknowledge that the study could not prove cause and effect and that electronic health records may contain diagnostic coding errors. Laboratories and clinics that cite this paper should carry those limitations forward rather than presenting the associations as established efficacy.
What remains uncertain
Joshua J. Joseph, M.D., M.P.H., FAHA, a volunteer expert at Ohio State University Wexner Medical Center who was not involved in the study, said GLP-1 RA medications may help people with PAD and Type 2 diabetes live longer and reduce amputation risk and hospitalizations, but that more research is needed to confirm these findings and understand the underlying mechanisms. He also flagged an open question: whether GLP-1 RAs benefit people with PAD who do not have Type 2 diabetes.
That question has direct implications for trial design and for how broadly the class might eventually be positioned. Until randomized or prospective data are available, the appropriate reading is that GLP-1 RA use was associated with better limb and survival outcomes in this record review — not that it has been shown to cause them. The American Heart Association notes that statements and conclusions in each manuscript are solely those of the study authors and that the Association makes no guarantee as to accuracy or reliability.
What comes next
Several developments are worth watching. First, whether prospective studies confirm the mortality and amputation signals, and whether they include PAD patients without diabetes. Second, whether prescribing guidance for PAD patients with Type 2 diabetes shifts in response to this and related evidence. Third, how clinics and telehealth platforms document product provenance and regulatory status as GLP-1 demand broadens from weight management into vascular risk reduction.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence; visit PeptideDDP.com for the latest first-hand information and industry updates.
Frequently asked questions
Did this study prove that GLP-1 drugs reduce deaths in PAD?
No. It was a retrospective review of electronic health records that found an association between GLP-1 RA use and lower rates of death, amputation, hospitalization and revascularization compared with metformin. The authors state the study could not prove cause and effect.
How many patients were included?
The overall PAD group included 3,224 GLP-1 RA users and 6,087 non-users; after matching, 2,133 patients per group were analyzed.
Are GLP-1 peptides approved for peripheral artery disease?
Approval status must be checked for the specific drug product, formulation and indication in the FDA’s Drugs@FDA database and current prescribing information. This study does not change any approved indication.
Does this apply to research-use-only GLP-1 peptides?
No. Research peptides are intended for laboratory use and are not authorized for human administration. Clinical use requires an approved or lawfully compounded prescription product under medical supervision.